Potential antitumor agent from the endophytic fungus Pestalotiopsis photiniae induces apoptosis via the mitochondrial pathway in HeLa cells

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1773-1781

  Chen, Chuan ^a,b   Hu, Shu Yuan ^a,b   Luo, Du Qiang ^a   Zhu, Si Yu ^a   Zhou, Chuan Qi ^a  

^a HEBEI UNIVERSITY   (China)

^b The Key Laboratory of Microbial Diversity Research and Application of Hebei Province   (China)

Author keywords

4 (3',3' dimethylallyloxy) 5 methyl 6 methoxyphthalide; Apoptosis; HeLa cells; Mitochondrial pathway

Indexed keywords

4 (3',3' DIMETHYLALLYLOXY) 5 METHYL 6 METHOXY PHTHALIDE; ANTINEOPLASTIC AGENT; BIM PROTEIN; CASPASE 9; CASPASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1C; MESSENGER RNA; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN E6; PROTEIN E7; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BAD GENE; BAX GENE; BIM GENE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN MCF 7; DRUG STRUCTURE; ENDOPHYTE; ENZYME ACTIVATION; FUNGUS; HELA CELL; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR MECHANICS; NOXA GENE; PESTALOTIOPSIS PHOTINIAE; PRIORITY JOURNAL; PUMA GENE; STRUCTURE ANALYSIS; TUMOR GENE; UPREGULATION;

AMINO ACID CHLOROMETHYL KETONES; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; BENZOFURANS; CASPASE 3; CASPASE 9; CASPASE INHIBITORS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA-BINDING PROTEINS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HELA CELLS; HUMANS; MCF-7 CELLS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MEMBRANE PROTEINS; MITOCHONDRIA; NUCLEAR PROTEINS; OLIGOPEPTIDES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION; UTERINE CERVICAL NEOPLASMS; XYLARIALES;

EID: 84882730509     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2618     Document Type: Article

References (37)

1. Koehn FE and Carter GT: The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4: 206-220, 2005.
2. Miller KI, Qing C, Sze DM and Neilan BA: Investigation of the biosynthetic potential of endophytes in traditional Chinese anticancer herbs. PLoS One 7: e35953, 2012.
3. Tan RX and Zou WX: Endophytes: a rich source of functional metabolites. Nat Prod Rep 18: 448-459, 2001.
4. Reed JC: Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol 3: 388-398, 2006.
5. Frankfurt OS and Krishan A: Apoptosis-based drug screening and detection of selective toxicity to cancer cells. Anticancer Drugs 14: 555-561, 2003.
6. Chen F, Wang W and El-Deiry WS: Current strategies to target p53 in cancer. Biochem Pharmacol 80: 724-730, 2010.
7. Collavin L, Lunardi A and Del Sal G: p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ 17: 901-911, 2010.
8. Ferreira CG, Tolis C and Giaccone G: p53 and chemosensitivity. Ann Oncol 10: 1011-1021, 1999.
9. Lunghi P, Costanzo A, Mazzera L, Rizzoli V, Levrero M and Bonati A: The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. Clin Cancer Res 15: 6495-6502, 2009.
10. Bisso A, Collavin L and Del Sal G: p73 as a pharmaceutical target for cancer therapy. Curr Pharm Des 17: 578-590, 2011.
11. Slade N and Horvat A: Targeting p73 - a potential approach in cancer treatment. Curr Pharm Des 17: 591-602, 2011.
12. Lain S, Hollick JJ, Campbell J, et al: Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13: 454-463, 2008.
13. Vassilev LT, Vu BT, Graves B, et al: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848, 2004.
14. Peirce SK and Findley HW: The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. Int J Oncol 34: 1395-1402, 2009.
15. Sampath D, Calin GA, Puduvalli VK, et al: Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 113: 3744-3753, 2009.
16. Phuwapraisirisan P, Rangsan J, Siripong P and Tip-Pyang S: New antitumour fungal metabolites from Alternaria porri. Nat Prod Res 23: 1063-1071, 2009.
17. Suemitsu R, Ohnishi K, Morikawa Y and Nagatomo S: Zinnimidine and 5-(3',3'-dimethylallyloxy)-7-methoxy-6-methylphthalide from Alternaria porri. Phytochemistry 38: 495-497, 1995.
18. Yang XL, Zhang S, Hu QB, Luo DQ and Zhang Y: Phthalide derivatives with antifungal activities against the plant pathogens isolated from the liquid culture of Pestalotiopsis photiniae. J Antibiot (Tokyo) 64: 723-727, 2011.
19. Malumbres M and Barbacid M: To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1: 222-231, 2001.
20. Hengst L and Reed SI: Translational control of p27KIP1 accumulation during the cell cycle. Science 271: 1861-1864, 1996.
21. Pagano M, Tam SW, Theodoras AM, et al: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685, 1995.
22. Vervoorts J and Lüscher B: Post-translational regulation of the tumor suppressor p27(KIP1). Cell Mol Life Sci 65: 3255-3264, 2008.
23. Harbour JW and Dean DC: The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 14: 2393-2409, 2000.
24. Danial NN and Korsmeyer SJ: Cell death: critical control points. Cell 116: 205-219, 2004.
25. Chipuk JE and Green DR: How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 18: 157-164, 2008.
26. Ashkenazi A and Dixit VM: Death receptors: signaling and modulation. Science 281: 1305-1308, 1998.
27. Chipuk JE and Green DR: Do inducers of apoptosis trigger caspase-independent cell death? Nat Rev Mol Cell Biol 6: 268-275, 2005.
28. Brooks CL and Gu W: p53 ubiquitination: Mdm2 and beyond. Mol Cell 21: 307-315, 2006.
29. Sullivan KD, Gallant-Behm CL, Henry RE, Fraikin JL and Espinosa JM: The p53 circuit board. Biochim Biophys Acta 1825: 229-244, 2012.
30. Diaz D, Santander MA and Chavez JA: HPV-16 E6 and E7 oncogene expression is downregulated as a result of Mdm2 knockdown. Int J Oncol 41: 141-146, 2012.
31. Chipuk JE and Green DR: Dissecting p53-dependent apoptosis. Cell Death Differ 13: 994-1002, 2006.
32. Hemann MT and Lowe SW: The p53-Bcl-2 connection. Cell Death Differ 13: 1256-1259, 2006.
33. Villunger A, Michalak EM, Coultas L, et al: p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302: 1036-1038, 2003.
34. Wu Z, Zheng S and Yu Q: The E2F family and the role of E2F1 in apoptosis. Int J Biochem Cell Biol 41: 2389-2397, 2009.
35. Stiewe T and Pützer BM: Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 26: 464-469, 2000.
36. Mebratu Y and Tesfaigzi Y: How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle 8: 1168-1175, 2009.
37. Amin AR, Paul RK, Thakur VS and Agarwal ML: A novel role for p73 in the regulation of Akt-Foxo1a-Bim signaling and apoptosis induced by the plant lectin, Concanavalin A. Cancer Res 67: 5617-5621, 2007.